Stay updated on Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has undergone significant updates regarding a clinical study on pembrolizumab and mifepristone for advanced breast cancer, including changes to the study's design and safety evaluation process. Notably, the study will now pause enrollment after the first 10 patients for a safety evaluation before continuing with two cohorts.SummaryDifference50%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.